Atreca Inc
F:0C1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Getin Holding SA
WSE:GTN
|
PL |
|
B
|
Banco Santander Brasil SA
BOVESPA:SANB3
|
BR |
|
Foran Energy Group Co Ltd
SZSE:002911
|
CN |
|
S
|
Seshasayee Paper and Boards Ltd
BSE:502450
|
IN |
Atreca Inc
Depreciation & Amortization
Atreca Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Atreca Inc
F:0C1
|
Depreciation & Amortization
$5.5m
|
CAGR 3-Years
48%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Atreca Inc
Glance View
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.
See Also
What is Atreca Inc's Depreciation & Amortization?
Depreciation & Amortization
5.5m
USD
Based on the financial report for Dec 31, 2022, Atreca Inc's Depreciation & Amortization amounts to 5.5m USD.
What is Atreca Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
35%
Over the last year, the Depreciation & Amortization growth was 20%. The average annual Depreciation & Amortization growth rates for Atreca Inc have been 48% over the past three years , 35% over the past five years .
